These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38772169)

  • 1. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
    Boscolo Bielo L; Trapani D; Nicolò E; Valenza C; Guidi L; Belli C; Kotteas E; Marra A; Prat A; Fusco N; Criscitiello C; Burstein HJ; Curigliano G
    Cancer Treat Rev; 2024 Jul; 128():102761. PubMed ID: 38772169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
    Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
    Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
    [No Abstract]   [Full Text] [Related]  

  • 4. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
    Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
    Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
    Beith J; Burslem K; Bell R; Woodward N; McCarthy N; De Boer R; Loi S; Redfern A
    Asia Pac J Clin Oncol; 2016 Mar; 12 Suppl 1():3-18. PubMed ID: 27001208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
    Montemurro F; Di Cosimo S; Arpino G
    Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.
    Kaur P; Nagaraja GM; Zheng H; Gizachew D; Galukande M; Krishnan S; Asea A
    BMC Cancer; 2012 Mar; 12():120. PubMed ID: 22452810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
    J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.